Fig. 1



C5a bioactivity (100%)
1.5
1.0
0.5
0.0
Con
None
24
29
30
31
32
35
36
37
30, 37
40
53
64
65
66
68
64, 68
66, 68
69
70
C-del
rhC5a
C5a mutation sites

Fig. 2



Binding Capability (%)
125
100
75
50
25
0
Con
C5a
29 M
30 M
31 M
32 M
37 M
40 M
53 M
64 M
65 M
66 M
68 M
69 M
70 M
rhC5a

Fig. 3



Binding Capability (%)
125
100
75
50
25
0
Con
C5a
29 M
30 M
31 M
32 M
37 M
40 M
53 M
64 M
65 M
66 M
68 M
69 M
70 M
rhC5a

Fig. 4



Control plasma
INab708 treated plasma
INab308 treated plasma
F20 treated plasma
CH50
OD (450 nM)
0.5
0.4
0.3
0.2
0.1
0.0
0
0.125
0.175
0.2
0.225
0.25
0.275
1:20 plasma (ml)

Fig. 6




Ab:C5a=2:1
Ab:C5a=1:1
IL-8 (pg/ml)
3000
2400
1800
1200
600
0
Control
None
INab308
INab708
L2B23
E.coli (5x10⁶/ml)

Fig. 5


A
A: INab308
Fluorescence
20000
15000
10000
5000
0
94%
Con
Ab
C5a (16.7 nM)
Ab + C5a (1:2)
B
B: INab708
Fluorescence
20000
15000
10000
5000
0
100%
Con
Ab
C5a (16.7 nM)
Ab + C5a (1:2)
C
C: L2B23
Fluorescence
10000
7500
5000
2500
0
12%
Con
Ab
C5a (16.7 nM)
Ab + C5a (1:2)